
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Compugen (CGEN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CGEN (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6.25
1 Year Target Price $6.25
4 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 210.59% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 137.10M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 4 | Beta 2.62 | 52 Weeks Range 1.13 - 2.66 | Updated Date 08/28/2025 |
52 Weeks Range 1.13 - 2.66 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.06 | Actual -0.08 |
Profitability
Profit Margin -87.45% | Operating Margin (TTM) -670.57% |
Management Effectiveness
Return on Assets (TTM) -11.43% | Return on Equity (TTM) -35.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45299379 | Price to Sales(TTM) 6.19 |
Enterprise Value 45299379 | Price to Sales(TTM) 6.19 | ||
Enterprise Value to Revenue 2.05 | Enterprise Value to EBITDA -19.16 | Shares Outstanding 93535400 | Shares Floating 91623494 |
Shares Outstanding 93535400 | Shares Floating 91623494 | ||
Percent Insiders 2.03 | Percent Institutions 16.52 |
Upturn AI SWOT
Compugen

Company Overview
History and Background
Compugen Ltd. was founded in 1993 in Israel. It is a computational drug discovery company focused on discovering novel drug targets and developing therapeutics, primarily in immuno-oncology.
Core Business Areas
- Drug Discovery: Compugen utilizes its computational discovery platforms to identify novel drug targets, particularly in immuno-oncology.
- Therapeutic Development: The company develops therapeutic candidates based on its discovered targets, advancing them through preclinical and clinical stages.
- Licensing and Partnerships: Compugen aims to monetize its discoveries through licensing agreements and partnerships with pharmaceutical companies.
Leadership and Structure
The company is led by a management team with experience in biotechnology and drug development. The organizational structure typically includes research, development, clinical, and business development departments.
Top Products and Market Share
Key Offerings
- COM701: A first-in-class antibody targeting PVRIG, a novel immune checkpoint, currently in clinical trials for solid tumors. Market share data is not yet available as it is still in clinical development. Competitors include companies developing similar checkpoint inhibitors, such as those targeting PD-1/PD-L1. Potential competitors with overlapping mechanisms are still emerging.
- BAY 1905254 (formerly COM902): A first-in-class antibody targeting TIGIT, being developed in collaboration with Bayer. Market share data is not available as it is still in clinical development. Competitors include companies like Roche (TIGIT inhibitor tiragolumab), Gilead (domvanalimab), and Arcus Biosciences.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, focused on developing therapies that harness the body's immune system to fight cancer.
Positioning
Compugen positions itself as an innovator in computational drug discovery, specializing in identifying novel immune checkpoint targets. Its competitive advantage lies in its proprietary computational platforms and first-in-class assets.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is expected to reach hundreds of billions of dollars in the coming years. Compugen is positioned to capture a share of this market through the successful development and commercialization of its pipeline assets.
Upturn SWOT Analysis
Strengths
- Proprietary computational drug discovery platforms
- Novel immune checkpoint targets (PVRIG, TIGIT)
- Strategic partnerships with major pharmaceutical companies (Bayer)
- First-in-class therapeutic candidates
- Strong intellectual property portfolio
Weaknesses
- Reliance on clinical trial success
- High R&D costs
- Competition from larger pharmaceutical companies
- Limited revenue stream
- Dependency on partners for commercialization
Opportunities
- Expansion of pipeline with new drug targets
- Successful clinical trial outcomes for COM701 and BAY 1905254
- Further collaborations and licensing agreements
- Advancements in computational biology and AI
- Personalized medicine and biomarker discovery
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immuno-oncology therapies
- Patent challenges
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Gilead (GILD)
- Arcus Biosciences (RCUS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Compugen's advantage lies in its novel targets, but it faces strong competition from larger companies with more resources and established products.
Major Acquisitions
Not Applicable
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: NA
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline and the securing of partnerships with pharmaceutical companies.
Future Projections: Future growth is contingent on successful clinical trial outcomes for COM701 and BAY 1905254, as well as the development of new drug targets. Analyst estimates would be the best source for revenue projections.
Recent Initiatives: Recent strategic initiatives include ongoing clinical trials for COM701, continued collaboration with Bayer on BAY 1905254, and the advancement of new preclinical programs.
Summary
Compugen is a computational drug discovery company with promising novel targets and strategic partnerships that could lead to future growth. However, it faces risks associated with clinical trials and competition from larger pharmaceutical firms. Success hinges on the development of its pipeline, and it is still considered a risky stock due to its developmental stage. The company's computational drug discovery approach offers a unique advantage, but it needs to validate this approach with successful commercial products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Compugen's investor relations website
- SEC filings
- Company press releases
- Analyst reports (various sources)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source and methodology. Financial data is based on publicly available information. Always conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compugen
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2000-08-11 | CEO, President & Director Dr. Anat Cohen-Dayag Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://cgen.com |
Full time employees 74 | Website https://cgen.com |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.